Medical Cannabinoids and Paradoxical Vomiting: A CBD Case

Medical cannabis case studies · Literature checked 2 October 2026

A medicine can produce an unexpected adverse effect even when it is being used for a legitimate medical purpose. A 2023 report described recurrent severe vomiting in a child receiving cannabidiol for difficult-to-treat epilepsy. The clinicians suspected cannabinoid hyperemesis syndrome, or CHS. This is a safety signal from one complex clinical case, not a measure of how commonly prescription CBD causes the syndrome. [1]

Evidence at a glance: one published paediatric case with improvement after supervised withdrawal, supported by broader prescription-cannabinoid warnings about paradoxical vomiting. The precise cause and frequency remain uncertain.

Black-and-white anatomical illustration showing the stomach, small intestine and large intestine within the torso. — Digestive-system anatomy. Recurrent vomiting needs clinical assessment; this illustration is not an image of the reported patient. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. Copyright-free public-domain illustration.

The reported clinical course

The child had Lennox–Gastaut syndrome and had received CBD since age eleven. At thirteen, a ketogenic diet reduced seizure frequency, but over the next six months he had five bouts of severe vomiting, roughly monthly and lasting 24–48 hours. Investigation also found delayed gastric emptying. A motility specialist suspected CHS. CBD was gradually withdrawn; vomiting resolved within two months and had not required further hospitalisation at almost one year. The report described no associated increase in seizures, while the ketogenic diet continued. [1]

Why the improvement after withdrawal is informative

Clinicians call improvement after stopping a suspected medicine a dechallenge. It strengthens a possible causal link, especially when the timing fits. It does not, by itself, prove the mechanism or exclude every competing explanation. A patient can have more than one contributor to vomiting, and changes in feeding, other medicines and the underlying illness may matter.

In this case the sequence is important: the symptom pattern changed in the setting of an already complicated treatment programme. It would be inaccurate to simplify that into “the first dose of CBD caused vomiting” or to imply that every episode of nausea on a cannabinoid is CHS. The syndrome is a clinical interpretation of a pattern, not a label automatically attached to any gastrointestinal complaint.

How can a cannabinoid have an apparently opposite effect?

Some prescription cannabinoids are used against nausea and vomiting. Yet the official dronabinol label also warns that treatment can produce or worsen nausea, vomiting and abdominal pain, sometimes with dehydration or electrolyte disturbance. This is described as a paradoxical reaction. Dronabinol is THC, so this warning is contextual evidence about a different medicine; it cannot establish the mechanism or frequency of CBD-associated CHS. [2]

“Cannabinoid” names a broad group, not a single interchangeable drug. A side effect reported with one member should prompt careful investigation rather than an assumption that all members carry the same risk at the same rate. Equally, a medicine’s usual therapeutic purpose should not prevent clinicians considering it as a possible contributor to a new symptom.

Food and treatment changes deserve attention

The current Epidyolex patient leaflet instructs patients to take the medicine consistently with respect to food, including high-fat meals and ketogenic diets. It also warns against abruptly stopping treatment because seizures may worsen. Those instructions make changes in feeding and medication relevant to a clinical review, but they do not prove that the diet caused the vomiting in the published case. [3]

The distinction is between a plausible explanation and a demonstrated explanation. The case supports asking about timing and exposures. It does not establish a universal interaction between ketogenic diets and CBD, or a reason to abandon an effective epilepsy treatment without specialist advice.

A misleading “case report” excluded from the evidence

A separate 2022 palliative-care paper has a case-report title and describes nabilone-associated vomiting. However, its ethics statement explicitly says the account was a demonstrative vignette and no patients were involved. It is therefore not counted here as an observed patient case. That distinction matters when searching for unusual events: a plausible clinical illustration is not independent evidence that an event occurred in a real patient. [4]

The practical lesson for patients and clinicians

Persistent or severe vomiting during treatment needs medical assessment, including attention to hydration and whether essential medicines can be retained. A useful history records when episodes began, recent product or dose changes, meals or feeds, other medicines and associated symptoms. The treating team can assess alternative causes and decide whether a supervised treatment change is appropriate.

Do not recreate a withdrawal experiment at home, particularly when CBD is prescribed for epilepsy. The absence of worsening seizures in one report cannot predict another patient’s response. The value of this unusual case is that it widens the clinical question: a prescribed cannabinoid may deserve consideration in the medication review even when the presenting symptom seems unrelated to the reason it was started.

This article explains published clinical evidence. Individual cases cannot predict personal treatment response. Decisions about prescription medicines belong with the treating clinician.